Results 221 to 230 of about 22,201 (271)

Rapid intravenous symptom-inhibiting fentanyl induction (SIFI) to optimize rotation onto oral opioid agonist therapy among individuals who use unregulated fentanyl: protocol for an open-label, single arm clinical trial. [PDF]

Addict Sci Clin Pract
Azar P, Ignaszewski MJ, Harris M, Barazanci Z, Davison R, Wong JSH, Maharaj A, Mathew N, Hall D, Guillemi SA, Foreman J, Barrios R, Montaner JSG.   +12 more
europepmc   +1 more source

Differential Impacts of Methadone and Buprenorphine/Naloxone on Pain‐Related Outcomes Among People With Non‐Heroin Opioid Use Disorder: Secondary Analyses From a Pragmatic Canadian Multisite Trial

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction In addition to their use as opioid agonist therapy (OAT), methadone and buprenorphine/naloxone also have analgesic properties. However, there is limited information on the relative effectiveness of these medications for analgesia in the context of treatment for non‐heroin opioid use disorder (OUD).
Katie Lyman, JinCheol Choi, Didier Jutras‐Aswad, Bernard L. E. Foll, Sukhpreet Klaire, M. Eugenia Socias   +5 more
wiley   +1 more source

Intranasal Mucosal Atomiser Devices: A Novel Harm Reduction Intervention

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Factors associated with diminished peripheral vein access, including age, prolonged history of injecting drug use and coadministration with other substances, are all increasing among people who inject drugs in Australia. This exposes individuals to increased risk of injecting related complications, including skin and soft tissue ...
Hayden Green, Thileepan Naren, Brittany Chapman, Martyn Lloyd‐Jones, Sione Crawford, Dean Membrey   +5 more
wiley   +1 more source

Sustainability of opioid agonist therapy programmes in Belarus, the Republic of Moldova, Tajikistan and Ukraine in the context of transition from Global Fund support during 2020-2023. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Malikov N, Dvoriak S, Filippovych M, Latypov A, Kralko A, Iatco A, Cook C.   +8 more
europepmc   +1 more source

Effectiveness of Alcohol Use Disorder Pharmacotherapies by Sex: Systematic Review and Meta‐Analysis

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Issues Alcohol use disorder (AUD) shows sex‐related differences in prevalence, harm and treatment response. Despite growing interest in sex differences, evidence synthesis evaluating pharmacotherapy effectiveness by sex remains limited. Approach Web of Science, PubMed, Scopus, PsycINFO and Cochrane were searched twice.
Juliette Allen, Andrew Jones, Gillian W. Shorter, Catharine Montgomery, Zetta Kougiali, Alina Bagnall, Claire Adshead, Jessie Smith, Sam Burton, Amanda Atkinson, Lillian Guelen, Abigail Rose   +11 more
wiley   +1 more source

Measuring sustainability of opioid agonist therapy programs in the context of transition from global fund support. [PDF]

Harm Reduct J
Stuikyte R, Varentsov I, Cook C, Dvoriak S.   +3 more
europepmc   +1 more source

Perceptions of Buprenorphine With Naloxone Treatment and the Fear of Precipitated Withdrawal: A Qualitative Exploration With HIV Prevention Trials Network 094 INTEGRA Participants and Staff

Drug and Alcohol Review, Volume 45, Issue 5, July 2026.
ABSTRACT Introduction Uptake of evidence‐based medication for opioid use disorder (MOUD), including buprenorphine–naloxone, remains low despite the expanding US opioid crisis. This study examined participants' and staff perceptions of adopting and delivering buprenorphine–naloxone on a mobile unit providing integrated MOUD and HIV services for people ...
Rose A. Schmidt, Amaya Perez‐Brumer, Peter Davidson, Steve Shoptaw, Nabila El‐Bassel, Philip Andrew, Jayla Harris, Omar Nieto, Sydney Bornstein, Rashaunna Redd, Jessica Yeager, David Goodman‐Meza, Albert L. Hasson, Marc Seigel, Cecile Denis, Renee El‐Krab, Laramie R. Smith, on behalf of the HPTN 094 Team   +17 more
wiley   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5767-5778, July 2026.
ABSTRACT Aims To investigate the association between use of GLP‐1 receptor agonists and incident Parkinson's disease. Material and Methods Cohort study using data from nationwide registers in Denmark, Norway and Sweden and an active‐comparator, new‐user design.
Arvid Engström, Henrik Svanström, Anders Hviid, Björn Eliasson, Soffia Gudbjörnsdottir, Viktor Wintzell, Kristian Hveem, Christian Jonasson, Mads Melbye, Peter Ueda, Björn Pasternak   +10 more
wiley   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, Volume 28, Issue 7, Page 5740-5750, July 2026.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source